Download to read offline
More Related Content
Similar to 10 Infectious Mononucleosis 2 Managment.ppt
![Epstein barr virus [autosaved]](https://cdn.slidesharecdn.com/ss_thumbnails/epsteinbarrvirusautosaved-211025044258-thumbnail.jpg?width=640&height=640&fit=bounds)
More from arahmanzai5
10 Infectious Mononucleosis 2 Managment.ppt
- 1.
- 2. • Infectious Mononucleosis (IM;also known as EBV infectious mononucleosis or glandular fever or Pfeiffer's disease or Filatov's disease and sometimes colloquially as the kissing disease from its oral transmission or simply as mono in North America and as glandular fever in other English-speaking countries) is an infectious, widespread viral disease caused by the Epstein-Barr virus (EBV).
- 3. Infectious Mononucleosis : Cause •EBV 90% of acute IM • Etiology of most EBV-negative IM : unknown • Other Herpesviruses : – Cytomegalovirus (CMV) – herpes simplex 1 and simplex 2 – human herpesvirus 6 • Other viruses : – adenovirus – hepatitis A, hepatitis B, or hepatitis C – rubella – primary human immunodeficiency virus in adolescents or young adults.
- 4. VIROLOGY. • Epstein BarrVirus (EBV) – Herpes Family – (linear DNA virus HHV4) – Surrounded by nucleocapsid and glycoprotein envelope • Also associated with nasopharyngeal carcinoma, Burkitts lymphoma, Hodgkins Disease, B cell lymphoma.
- 5. Virology : Structureand Genome • The structure of EBV is typical for a member of herpesvirus family : Inner core of DNA surrounded by a nucleocapsid, tegument,and an envelope. • The entire EBV genome : short and long sections of “unique” sequences (Us and UL)
- 6. Epidemiology : Incidence •Population-based studies ; 90% of population have been infected or have antibodies to the virus. • Highest incidence rates : 15-19 years. • No seasonal predilection. • Higher rate in persons of white race than in other ethnic groups.
- 7. Epidemiology : Seroprevalence •In the mid-1960s : detection of antibodies to - VCA (long lasting, early in infection) - EA (short duration, early in infection) • EBV-VCA antibodies : 85% in normal adults • 80-95% of adults have serologic evidence, most infections occuring during infancy and children.
- 8. Primary EBV infection: Seroprevalence • In developing countries -80-100% of children becoming infected by 3-6 yrs of age -clinically silent or mild disease. • In developed countries -occurs later in life, 10-30 years of age -induce clinically mononucleosis syndrome (U.S.college students : 50-75% associated with primary EBV infection)
- 9.
- 10. Epidemiology : Transmission •Incubation period : 30 – 50 days. (shorter in young children) • Oral secretion : major role but occur slowly • Blood products,Transplanted organs : less commonly than CMV • Intrauterine : infrequently : if infected; no adverse fetal outcomes and no viral transmission to the fetus.
- 11. Pathophysiology • Reservoir ofEBV : Humans only. • EBV founds in the saliva for the first 12-18 months after acquisition. • Viral replication – lymphoreticular system – liver – spleen – B lymphocytes in peripheral blood.
- 12. Pathophysiology • Host immuneresponse to the viral infection – atypical lymphocytes. • After acute EBV infection, latently infected lymphocytes and epithelial cells persist and are immortalized. • During latent infection, the virus is present in the lymphocytes and oropharyngeal epithelial cells as episomes in the nucleus.
- 13. Pathophysiology • A lowrate of viral reactivation occurs within the population of latently infected cells. • Primary source of new virus in latently infection – Epithelial cells. • Virus can be isolated from oral secretions of 20-30% of healthy latently infected individuals at anytime.
- 14. Molecular Biology :Replication • To infect cells, EBV uses a cell surface receptor (CR2,CD21) found primarily on B lymphocytes and nasopharyngeal epithelial cells. • MHC class II protein functions as a cofactor for this virus- receptor interaction. • After infection of epithelial cells, active replication occurs and leads to lysis and death of the cell.
- 15. Molecular Biology :Replication • Viral capsid antigens (VCAs) are the primary structure protiens in viral capsids and are found in replicating cells. • EBV early antigens (EAs) consist of >15 protiens codes by genes distributed throughout the genome. • EBV nuclear antigen (EBNA) corresponds to six virally encoded protiens found in the nucleus of an EBV-infected cell.
- 16. Viral capsid antigens(VCAs)
- 17. Molecular Biology :Latency • Latently infected B cells are the primary reservoir of EBV in the body. • >100 gene products may be expressed during active viral replication, only 11 are expressed during viral latency. • In this way, the virus limits cytotoxic T-cell recognition of EBV-infected cells.
- 18. • EBV generallytransforms relatively mature B lymphocytes secreting a complete immunoglobulin product. • EBV : infect and transform B cells in earlier stages of development (e.g. pre-B cells and lymphoid precusors lacking immunoglobulin gene rearrangement) Molecular Biology : Transformation
- 19. Molecular Biology :EBV Subtype • 2 subtypes • EBV-1 (type A): Western countries EBV-2 (type B): less virulence • In immunocompromised persons : co-infection both type 1 and type 2 strains • No one subtype is responsible for specific lymphoproliferative diseases (geographic differences)
- 20.
- 21.
- 22. Serum Epstein-Barr Virus(EBV) Antibodies in EBV Infection Infection Infection VCA IgG VCA IgG VCA VCA IgM IgM EA(D) EA(D) EBNA EBNA No previous No previous infection infection - - - - - - - - Acute Acute infection infection Recent Recent infection infection + + + + + + +/- +/- +/- +/- +/- +/- - - +/- +/- Past Past infection infection + + - - +/- +/- + +
- 23. Symptoms. • Acute infectiousmononucleosis – fatique and malaise 1-2 wks – sore throat, pharyngitis – retro-orbital headache – fever – myalgia – nausea – abdominal pain – generalized lymphadenopathy – hepatosplenomegaly
- 24. • Pharyngitis isthe most consistent physical finding. – 1/3 of patients : exudative pharyngitis. – 25-60% of patients : petechiae at the junction of the hard and soft palates. – Tonsillar enlargement can be massive, and occasionally it causes airway obstruction.
- 25. • Lymphadenopathy :90% – symmetrical enlargement. – mildly tender to palpation and not fix. – posterior cervical lymph nodes. – anterior cervical and submandibular nodes. – axillary and inguinal nodes. – Enlarged epitrochlear nodes are very suggestive of infectious mononucleosis.
- 26. • Hepatomegaly :60% – jaundice is rare. – Percussion tenderness over the liver is common. • Splenomegaly : 50% – palpable 2-3 cm below the left costal margin and may be tender. – rapidly over the first week of symptoms, usually decreasing in size over the next 7-10 days. – spleen can rupture from relatively minor trauma or even spontaneously.
- 27. • Maculopapular rash: 15% – usually faint, widely scattered, and erythematous – occurs in 3-15% of patients and is more common in young children. – 80% of patients, treatment with amoxicillin or ampicillin is associated with rash – Circulating immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to ampicillin are demonstrable.
- 28. Infectious Mononucleosis IM withrash after treatment with amoxicillin or ampicillin IM with rash after treatment with amoxicillin or ampicillin
- 29. Infectious Mononucleosis • Eyelidedema : 15% – may be present, especially in the first week • Children younger than 4 years : more commonly – splenomegaly or hepatomegaly – rash – symptoms of an upper respiratory tract infection
- 30. Clinical manifestation ofIM in children and adults Frequency (%) Sign or symptom Age < 4 yr Age 4 – 16 yr Adults (range) Lymphadenopathy 94 95 93 – 100 Fever 92 100 63 – 100 Sore throat or 67 75 70 – 91 tonsillopharyngitis Exudative 45 59 40 – 74 tonsillopharyngitis Splenomegaly 82 53 32 – 51 Hepatomegaly 63 30 6 – 24 Cough or rhinitis 51 15 5 – 31 Rash 34 17 0 – 15 Abdominal pain or 17 0 2 – 14 discomfort Eyelid edema 14 14 5 – 34
- 31.
- 32.
- 33.
- 35. Infectious Mononucleosis :Lab • The 3 classic criteria for laboratory confirmation 1 lymphocytosis 2 the presence of at least 10% atypical lymphocytes on peripheral smear 3 a positive serologic test for Epstein-Barr virus (EBV).
- 36. Infectious Mononucleosis :Lab • Complete blood count – 40-70%, Leukocytosis (WBC 10,000-20,000 cells per cm3) – By the second week of illness, approximately 10% have a WBC count > 25,000 per cm3. – 80-90% of patients have lymphocytosis, with greater than 50% lymphocytes. Lymphocytosis is greatest during 2-3 weeks of illness and lasts for 2-6 weeks. – 20-40% of the lymphocytes : atypical lymphocytes > 10% ; Downey types – 25-50%, Mild thrombocytopenia
- 37. Infectious Mononucleosis atypical lymphocytes atypicallymphocytes : : Downey types Downey types
- 38. Infectious Mononucleosis :Lab • Liver function tests – 80-100% of patients : elevated LFT – Alkaline phosphatase, AST and bilirubin peak 5-14 days after onset – GGT peaks at 1-3 weeks. Occasionally, GGT remains mildly elevated for up to 12 months – 95% of patients : elevated LDH – most liver function test results are normal by 3 months.
- 39. Infectious Mononucleosis :Lab • Heterophile antibodies – 50% in first week of illness – 60-90% in the second or third weeks – begins to decline during the fourth or fifth week and often is less than 1:40 by 2-3 months after symptom onset – 20% of patients have positive titers 1-2 years after acquisition – children < 2 years : 10-30% – children 2-4 years : 50-75%
- 40. Infectious Mononucleosis :Lab • EBV serology • EAs (early antigens) : early in the lytic cycle • VCA (Viral capsid antigen) and membrane antigens : late in the lytic cycle • EBNA (Epstein-Barr nuclear antigen) : latent infection • Antibodies to membrane antigens : usually are not measured
- 41. Infectious Mononucleosis :Lab – Time course of antibody production • EA is rising at symptom onset : rise for 3-4 weeks, then quickly decline to undetectable levels by 3-4 months, although low levels may be detected intermittently for years. • VCA-IgM usually is measurable at symptom onset, peaks at 2-3 weeks, then declines and unmeasurable by 3-4 months. • VCA-IgG rises shortly after symptom onset, peaks at 2-3 months, then drops slightly but persists for life. • EBNA : convalescence and remain present for life.
- 42. IM Treatment Medical Care: • self-limited illness : not require specific therapy. • Inpatient therapy of medical and surgical complications may be required. • Acyclovir (10 mg/kg/dose IV q8h for 7-10 d) – inhibit viral shedding from the oropharynx – clincal course is not significantly • IVIG (400 mg/kg/d IV for 2-5 d) – immune thrombocytopenia associated with
- 43. IM Treatment Medical Care: • Short-course corticosteroids : prednisolone (1 mg/kg/d, max 60 mg/d for 7 d and tapered over another 7 d) – Marked tonsillar inflammation with impending airway obstruction – Massive splenomegaly – Myocarditis – Hemolytic anemia – Hemophagocytic syndrome – Seizure and meningitis Surgical Care : • Splenic rupture.
- 44. Infectious Mononucleosis Activity : •depends on severity of the patient's symptoms. • Extreme fatigue : bed rest for 1-2 weeks. • Malaise may persist for 2-3 months. • Patients should not participate in contact sports or heavy lifting for at least 2-3 weeks • some authors recommend avoiding activities that may cause splenic trauma for 2 months.
- 45. IM : Complications •Hepatitis : > 90% of patients – LFT : < 2-3 times of NUL in the second and third weeks of illness – 45% of patients : elevated bilirubin, but jaundice occurs in only 5%. Mild thrombocytopenia occurs in approximately 50% of patients with infectious mononucleosis. • Platelet count : approximately 1 week after symptom onset (100,000-140,000/cm3. ), then gradually improves over the next 3-4 weeks. Mild thrombocytopenia occurs in approximately 50% of patients with infectious mononucleosis.
- 46. IM : Complications •Hemolytic anemia – 0.5-3%, associated with cold-reactive antibodies, anti-I antibodies, and with autoantibodies to triphosphate isomerase – mild and is most significant during the second and third weeks of symptoms. • Upper airway obstruction – 0.1-1%, due to hypertrophy of tonsils and other lymph nodes of Waldeyer ring – treatment with corticosteroids may be beneficial
- 47. • Splenic rupture: 0.1-0.2% – Spontaneous or history of some antecedent trauma. – occur during the second and third weeks. – mild-to-severe abdominal pain below the left costal margin, sometimes with radiation to the left shoulder and supraclavicular area. – Massive bleeding : Shock • Hematologic complications – hemophagocytic syndrome. – Immune thrombocytopenic purpura occurs and may evolve to aplastic anemia. – accelerate hemolytic anemia in congenital spherocytosis or hereditary elliptocytosis. – Disseminated intravascular coagulation associated with hepatic necrosis has occurred.
- 48. IM : Complications •Neurologic complications : < 1% – during the first 2 weeks. – negative for the heterophile antibody. – Severe (fatal), complete recovery – aseptic meningitis, acute viral encephalitis, coma, meningitis, and meningoencephalopathy. – Hypoglossal nerve palsy, Bell palsy, hearing loss, brachial plexus neuropathy, multiple cranial nerve palsies, Guillain-Barré syndrome, autonomic neuropathy, gastrointestinal dysfunction secondary to selective cholinergic dysautonomia, acute cerebellar ataxia, transverse myelitis. • Cardiac and pulmonary complications – rare – chronic interstitial pneumonitis. – myocarditis and pericarditis.
- 49. IM : Complications •Autoimmune complications – Autoimmune diseases and Reye syndrome have been associated with EBV infection. – Infectious mononucleosis stimulates production of many antibodies not directed against EBV. These include autoantibodies, anti-I antibodies, cold hemolysins, antinuclear antibodies, rheumatoid factors, cryoglobulins, and circulating immune complexes. These antibodies may precipitate autoimmune syndromes.
- 50. IM : Complications •Miscellaneous complications – Renal disorders : immune deposit nephritis, renal failure, paroxysmal nocturnal hemoglobinuria. – After cardiac bypass or transfusion, an infectious mononucleosis–like syndrome : primary CMV infection > EBV. – A syndrome of chronic fatigue, myalgias, sore throat, and mild cognitive dysfunction occurring primarily in young adult females initially was attributed to EBV. Current data suggest that EBV is not the etiologic agent .
- 51. IM : Prognosis •Immunocompetent : full recovery in several months. • The common hematologic and hepatic complications resolve in 2-3 months. • Neurologic complications – Children : resolve quickly – Adults : neurological deficits • All individuals develop latent infection – asymptomatic.
- 52.
- 53. Prevention • Isolation isnot required : low transmission. • Avoid contact with saliva. • Avoid kissing when in acute phase. • Maintain clean conditions : avoid sharing toys among children in day care. • Vaccine development is proceeding, although the role of a vaccine is unclear.
- 54.